Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patillo, Kammie
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease	Recruiting	2/3	344	Europe, Canada, US, RoW	Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets	Forma Therapeutics, Inc., Novo Nordisk A/S	Sickle Cell Disease	12/25	12/26
Oladipupo, Olatunde
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease	Recruiting	2/3	344	Europe, Canada, US, RoW	Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets	Forma Therapeutics, Inc., Novo Nordisk A/S	Sickle Cell Disease	12/25	12/26